TransEnterix (NYSE:TRXC) said today it filed an FDA 510(k) submission for its Senhance Ultrasonic instrument system, designed to operate with its Senhance robotic platform. The Research Triangle Park, N.C.-based company said that the approval would allow the system to utilize ultrasonic devices designed to deliver controlled energy to ligate and divide tissue and minimize thermal injury […]
TransEnterix shares fall despite Street-beating Q2
Shares in TransEnterix (NYSE:TRXC) fell today after the robotic surgical platform developer posted second quarter earnings that beat expectations on Wall Street, but showed growing losses. The Research Triangle Park, N.C.-based company posted losses of $34.3 million, or 17¢ per share, on sales of $6.4 million for the three months ended June 30, seeing losses grow […]
TransEnterix jumps on Q2 prelims
TransEnterix (NYSE:TRXC) shares got a jump today when the robot-assisted surgery company released preliminary revenue numbers for the second quarter that outstripped the consensus on Wall Street. Research Triangle Park, N.C.-based TransEnterix said it expects to post sales of $6.0 million to $6.3 million for the three months ended ended June 30, 2018, up 300% to […]
TransEnterix seeks expanded FDA indications for Senhance platform
TransEnterix (NYSE:TRXC) said yesterday it submitted a 510(k) submission to the FDA seeking clearance for extra instruments for its Senhance robotic surgical platform, including 3 mm diameter instruments. The Research Triangle Park, N.C.-based company said that the clearance would allow the Senhance to be used in microlaparoscopic surgeries. The platform is currently cleared for laparoscopic colorectal, […]
TransEnterix surges on expanded indications for Senhance robot-assisted surgery device
TransEnterix (NYSE:TRXC) said today that it won expanded indications from the FDA for its Senhance robot-assisted surgery device, which is now cleared for hernia and gallbladder procedures. The federal safety watchdog’s expanded 510(k) decision doubles the Research Triangle Park, N.C.-based company’s addressable market, president & CEO Todd Pope said in prepared remarks. “These expanded procedures are […]
TransEnterix shares rise on Street-beating Q1
Shares in TransEnterix (NYSE:TRXC) rose today after the medical device maker beat expectations on Wall Street with its first quarter earnings results. The Research Triangle Park, N.C.-based company posted losses of $882,000, or 0¢ per share, on sales of $4.8 million for the three months ended March 31, seeing losses shrink 94.3¢ while sales grew 145% […]
TransEnterix shares dip on Q4, 2017 earnings
Shares in TransEnterix (NYSE:TRXC) have fallen today after the medical device maker posted growing losses in its fourth quarter and full year 2017 earnings. The Research Triangle Park, N.C.-based company posted losses of $76.2 million, or 40¢ per share, on sales of $3.4 million for the three months ended December 31, seeing losses grow 444.3% while […]
TransEnterix files expanded 510(k) application for Senhance robotic platform
TransEnterix (NYSE:TRXC) said today it filed an FDA 510(k) submission looking to expand the indications for its Senhance robotic surgical platform to include laparoscopic inguinal hernia and laparoscopic cholecystectomy surgeries. The Research Triangle Park, N.C.-based company said that with the additional indications, its Senhance system would be cleared for use in the most common abdominal surgeries in […]
TransEnterix deals SurgiBot assets for $29m to China’s Great Belief International
TransEnterix (NYSE:TRXC) said today that it agreed to deal its SurgiBot assets to Chinese medtech investment firm Great Belief International for $29 million. The agreement calls for Research Triangle Park, N.C.-based TransEnterix to retain the distribution rights to SurgiBot, which it shelved last year, outside of the U.S. Get the full story on our sister site, The […]
TransEnterix opens the doors to a competitive US surgical robotics market
The surgical robotics market in the US has finally become competitive. In October, the FDA granted clearance to only the second robotic surgical system to date – TransEnterix‘s (NYSE:TRXC) Senhance laparoscopic platform. The clearance was a huge milestone for the Morrisville, N.C.-based company and was quickly followed by yet another – almost exactly a month after […]
TransEnterix logs first U.S. sale, meets Q3 earnings expectations
TransEnterix (NYSE:TRXC) shares jumped today after the medical device company said it sold its first Senhance robot-assisted surgery platform in the U.S., exactly a month after winning FDA clearance. The sale, to Florida Hospital in Orlando, follows another sale in Taiwan made during the third quarter, president & CEO Todd Pope said during a conference call […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube